Infantile Spasms Therapeutics Market Share Report 2023-2028

1
Global Infantile Spasms Therapeutics Market
Research and Forecast Report 2023-2028




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Infantile Spasms Therapeutics Market
Research Report According to the latest report
by IMARC Group, titled Infantile Spasms
Therapeutics Market Global Industry Trends,
Share, Size, Growth, Opportunity and Forecast
2023-2028 the global infantile spasms
therapeutics market reached a strong growth in
2022.  Infantile spasms therapeutics refer to
the treatment procedures used for treating
seizures or an epilepsy syndrome in young
children, usually aged between four months and a
year of age. An episode of spasm is characterized
by the body stiffening suddenly, arms, legs, and
head bending forward, the back arching, and
short, subtle seizures. Infantile spasm can be
caused by brain tumors, birth injuries, infection
of the brain, and genetic changes. There are a
number of therapeutic options that are available
for infantile spams, including steroids, hormone
therapy with corticotropin injection gel and
glucocorticoids, as well as antiseizure
medications. Infantile spasms therapeutics are
more likely to provide sustained results if they
are implemented within three weeks after the
spasms occur, and treatment can be done by
monotherapy or combination therapy. Infantile
spasms are diagnosed by physical examination,
neurological examination, MRI of the brain, and
blood and urine examinations. Request Free
Sample Report https//www.imarcgroup.com/infantil
e-spasms-therapeutics-market/requestsample
4
Report Description and Highlights
Report Description

Global Infantile Spasms Therapeutics Market
Trends The increasing prevalence of infantile
spasms among newborn babies is a significant
factor driving the growth of the market. This can
be attributed to a considerable rise in the birth
rates across the globe. In line with this, the
growing number of product approvals and presence
of strong pipelines drugs are impacting the
market positively. Continual technological
advancements in the treatment of infantile
spasms, such as the introduction of seizure alert
device for detecting seizures and alerting the
caregivers, are providing an impetus to the
market. Also, the widespread awareness regarding
early diagnosis and treatment is enhancing the
penetration rate of infantile spasm drugs,
thereby fueling the market growth. However,
various factors, such as lesser treatment success
rates, high cost of treatment, strict regulations
for drug approval, and the augmenting undiagnosed
patient pool, are impeding the growth of the
infantile spasms therapeutics market. On the
contrary, favorable initiatives and programs
conducted by the government and private
organizations of several countries for promoting
awareness regarding the medical condition is
creating a positive market outlook. The market is
further driven by the extensive research and
development (RD) activities conducted by the key
market players focusing on the development of
innovative drugs with higher success rates. Some
of the other factors contributing to the market
include the expanding healthcare expenditure,
rising number of collaborations, partnerships and
merger and acquisitions (MAs), rapid
urbanization, and inflating disposable income
levels. Looking forward, the market value is
projected to reach a strong growth during the
forecast period (2023-2028).
5
Report Description and Highlights
Report Description
Market Summary Therapeutic Class Insights
Anticonvulsants Corticosteroids
Others Drug Type Insights Vigab
atrin Adrenocorticotropic Hormone
Others (Phase III) Dosage Insights
Solid Liquid Route of Administration I
nsights Oral Parenteral
Others

6
Report Description and Highlights
Report Description
Distribution Channel Insights
Hospital Pharmacy Retail Pharmacy
Online Pharmacy End User Insights
Hospitals Clinics Others Regi
onal Insights North America
United States Canada
Asia Pacific China
Japan India
South Korea

7
Report Description and Highlights
Report Description
Australia Indo
nesia Others Europe
Germany France
United Kingdom
Italy Spain
Russia Others
Latin America Brazil
Mexico Others
Middle East and Africa Note We are updat
ing our reports, If you want latest primary and
secondary data (2023-2028) with Cost Module,
Business Strategy, Distribution Channel, etc.
Click request free sample report.

8
Report Description and Highlights
Report Description

• Competitive Landscape with Key Players
• Mallinckrodt plc ORPHELIA Pharma Teva Pharmaceutic
  als USA Inc. (Teva Pharmaceutical Industries
  Ltd.),Kindly note that this only represents a
  partial list of companies the complete list has be
  en provided in the report
• View Full Report with TOC List of Figure
  https//www.imarcgroup.com/infantile-spasms-therap
  eutics-market

9
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
12

Contact Us